T4IL15Δ is engineered, a bispecific biologic that selectively delivers IL-15 signaling to memory CD4 T cells, with minimal off-target stimulation, and provides a robust reactivation platform that could complement other reservoir-elimination strategies toward an HIV-1 cure.
Abstract
Antiretroviral therapy suppresses HIV-1 replication but cannot eliminate the latent viral reservoir persisting in memory CD4 T cells. Existing latency reversal candidates have yet to achieve robust viral reactivation at tolerable doses. We engineered T4IL15Δ, a bispecific biologic that selectively delivers IL-15 signaling to memory CD4 T cells, with minimal off-target stimulation. T4IL15Δ reactivated latent virus in 94% (48/51) of clinical samples ex vivo, 75% (15/20) of administrations in HIV-1-infected and ART-suppressed humanized mice, and 100% (6/6) of SIV-infected and ART-suppressed rhesus macaques at doses well tolerated. We also found that off-target stimulation of non-CD4 cells hindered HIV-1 reactivation ex vivo. T4IL15Δ provides a robust reactivation platform that could complement other reservoir-elimination strategies toward an HIV-1 cure.
Human immunodeficiency virus type 1 (HIV-1) causes progressive immune dysfunction and, if untreated, can lead to acquired immunodeficiency syndrome (AIDS). Although combination antiretroviral therapy (cART) effectively suppresses viral replication and has substantially improved outcomes for people living with HIV (PLWH...
Christopher Nieva, Emma Lai, M. Sarkandi et al.· Viruses· 0 citations
Antiretroviral therapy (ART) suppresses viraemia in people with human immunodeficiency virus (HIV), but HIV provirus persists indefinitely in CD4-expressing cells. Cells containing active provirus express viral proteins and have been successfully targeted using broadly neutralizing antibodies (bnAbs). In contrast, cell...
J. Deere, David Merriam, K. Machmach et al.· Nature Microbiology· 0 citations
The interruption of antiretroviral therapy (ART) in HIV-1 infected individuals leads to rapid viral rebound, highlighting the persistent challenge of eradicating HIV-1 reservoirs. Our previous study demonstrated that combined administration of N-803 (Anktiva) combined with the broadly neutralizing antibodies (bNAbs),...
M. Marichannegowda, S. Lim, C. Fennessey et al.· Virus Evolution· 0 citations
Abstract Objective Despite the success of combination antiretroviral therapy (cART) in suppressing HIV replication, viral reservoirs persist in a latent state in resting memory CD4+ T-cells, lymphoid tissue and spleen, as well as in glia within the central nervous system (CNS), necessitating lifelong treatment. Persist...
Lorissa I. McDougall, A. Abbasi, Mohammad M. Sajadi et al.· NeuroImmune Pharmacology and...· 0 citations
Inducing a broadly neutralizing antibody (bnAb) response is a key goal of HIV-1 vaccine development. Despite significant progress, it is unknown whether vaccine-primed B cells can be reactivated and matured to secrete bona fide bnAbs. In the IAVI C107/C110 single-arm, open-label human trial, VRC01-class memory B cells...
T. Caniels, Madhu S. Prabhakaran, S. Agrawal et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.